Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Duchemann

Showing results (11-20 of 83) with videos related to

Pageof 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)|May 7, 2021
Response to letter entitled: Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosisBoris Duchemann, Johan Pluvy, Bruno Crestani, et al.
EJNMMI Research|January 30, 2019
Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCISTLucas Goldfarb, Boris Duchemann, Kader Chouahnia, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2021
Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosisBoris Duchemann, Johan Pluvy, Bruno Crestani, et al.
Respiratory Medicine and Research|November 30, 2025
Organising pneumonia following amivantamab treatment: a case reportGaspard Naulleau, Lise Matton, Ioana Hutuca, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2022
Adoptive cell therapies in thoracic malignanciesJulie Lasvergnas, Marie Naigeon, Kader Chouahnia, et al.
Respiratory Medicine and Research|June 11, 2023
PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitorsJulie Lasvergnas, Vincent Fallet, Boris Duchemann, et al.
Journal of Cancer Research and Clinical Oncology|July 8, 2020
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutationThierry Landre, Gaetan Des Guetz, Kader Chouahnia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 29, 2021
Pitfalls in Cancer Evaluation in Case of Chronic Superior Vena Cava Obstruction: Vertebral Enhancement and Hot Quadrate Sign in the LiverJulie Lasvergnas, Margot Playe, Laura Saint-Val, et al.
Bulletin Du Cancer|October 10, 2020
[Nomadism of patients treated by radiotherapy in Île-de-France: Does our health system have as much money to waste?]Adrien Paix, Hosni Popotte, Christine Lévy, et al.
Therapeutic Advances in Medical Oncology|December 21, 2020
First-line immune-checkpoint inhibitor plus chemotherapy <i>versus</i> chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysisThierry Landre, Kader Chouahnia, Gaëtan Des Guetz, et al.
Pageof 9

Showing results (11-20 of 83) with videos related to

Sort By:
Pageof 9
European Journal of Cancer (Oxford, England : 1990)|May 7, 2021
Response to letter entitled: Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosisBoris Duchemann, Johan Pluvy, Bruno Crestani, et al.
EJNMMI Research|January 30, 2019
Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCISTLucas Goldfarb, Boris Duchemann, Kader Chouahnia, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2021
Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosisBoris Duchemann, Johan Pluvy, Bruno Crestani, et al.
Respiratory Medicine and Research|November 30, 2025
Organising pneumonia following amivantamab treatment: a case reportGaspard Naulleau, Lise Matton, Ioana Hutuca, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2022
Adoptive cell therapies in thoracic malignanciesJulie Lasvergnas, Marie Naigeon, Kader Chouahnia, et al.
Respiratory Medicine and Research|June 11, 2023
PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitorsJulie Lasvergnas, Vincent Fallet, Boris Duchemann, et al.
Journal of Cancer Research and Clinical Oncology|July 8, 2020
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutationThierry Landre, Gaetan Des Guetz, Kader Chouahnia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 29, 2021
Pitfalls in Cancer Evaluation in Case of Chronic Superior Vena Cava Obstruction: Vertebral Enhancement and Hot Quadrate Sign in the LiverJulie Lasvergnas, Margot Playe, Laura Saint-Val, et al.
Bulletin Du Cancer|October 10, 2020
[Nomadism of patients treated by radiotherapy in Île-de-France: Does our health system have as much money to waste?]Adrien Paix, Hosni Popotte, Christine Lévy, et al.
Therapeutic Advances in Medical Oncology|December 21, 2020
First-line immune-checkpoint inhibitor plus chemotherapy <i>versus</i> chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysisThierry Landre, Kader Chouahnia, Gaëtan Des Guetz, et al.
Pageof 9